The Antiemetic 5-HT₃ Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra, and Barbara S. Slusher

Department of Neurology (B.S.S.) and Brain Science Institute (C.R., M.S., J.A., A.G.T., B.S.S.), Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan (Y.L.); Eisai Inc., Baltimore, Maryland (J.Z.); and Helsinn Healthcare, Lugano, Switzerland (S.C., S.S., C.P.)

Received January 22, 2010; accepted August 18, 2010

ABSTRACT

Palonosetron is the only 5-HT₃ receptor antagonist approved for the treatment of delayed chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy. Accumulating evidence suggests that substance P (SP), the endogenous ligand acting preferentially on neurokinin-1 (NK-1) receptors, not serotonin (5-HT), is the dominant mediator of delayed emesis. However, palonosetron does not bind to the NK-1 receptor. Recent data have revealed cross-talk between the NK-1 and 5HT₃ receptor signaling pathways; we postulated that if palonosetron differentially inhibited NK-1/5-HT₃ cross-talk, it could help explain its efficacy profile in delayed emesis. Consequently, we evaluated the effect of palonosetron, granisetron, and ondansetron on SP-induced responses in vitro and in vivo. NG108-15 cells were preincubated with palonosetron, granisetron, or ondansetron; antagonists were removed and the effect on serotonin enhancement of SP-induced calcium release was measured. In the absence of antagonist, serotonin enhanced SP-induced calcium-ion release. After preincubation with palonosetron, but not ondansetron or granisetron, the serotonin enhancement of the SP response was inhibited. Rats were treated with cisplatin and either palonosetron, granisetron, or ondansetron. At various times after dosing, single neuronal recordings from nodose ganglia were collected after stimulation with SP; nodose ganglia neuronal responses to SP were enhanced when the animals were pretreated with cisplatin. Palonosetron, but not ondansetron or granisetron, dose-dependently inhibited the cisplatin-induced SP enhancement. The results are consistent with previous data showing that palonosetron exhibits distinct pharmacology versus the older 5-HT₃ receptor antagonists and provide a rationale for the efficacy observed with palonosetron in delayed CINV in the clinic.

Introduction

Nausea and vomiting are common, severe, and feared side effects of many chemotherapeutics. Inadequate control of chemotherapy-induced nausea and vomiting (CINV) impairs functional activity and may compromise adherence to treatment. 5-HT₃ receptor antagonists are most efficacious against acute emesis (0–24 h after chemotherapy administration), whereas neurokinin-1 (NK-1) receptor antagonists have been associated with the prevention of delayed emesis (24–120 h after chemotherapy administration) (Hesketh et al., 2003). Even though the terms acute and delayed are approximations with no clear distinction of when acute emesis ends and delayed emesis begins, they point to the idea that different mechanisms are at play. Palonosetron is unique among 5-HT₃ receptor antagonists in that, in addition to being effective against acute emesis, it has shown efficacy against delayed emesis (Eisenberg et al., 2003; Aapro et al., 2006; Saito et al., 2009). The reason for this unique efficacy in delayed emesis is not clear, because palonosetron does not bind to NK-1 receptors (Wong et al., 1995).

Receptor cross-talk, defined as activation of one receptor by its ligand affecting cellular responses to another receptor system, has been well described. Recent reports in the literature have shown that there is cross-talk between NK-1 and 5-HT₃ receptor signaling pathways. For example, substance...
Palonosetron, but Not Ondansetron or Granisetron, Inhibited Serotonin Enhancement of SP-Induced Calcium-Ion Release in NG-108-15 Cells. Calcium-ion release caused by SP alone or SP plus serotonin (10−7 M final concentration added immediately before measurement) was made by using a fluorometric imaging plate reader. **Results**

**Materials and Methods**

**Calcium-Ion Release Measurements in NG108-15 Cells.** NG108-15 cells, known to express both 5-HT3 and NK-1 receptors, were grown in high-glucose Dulbecco's modified Eagle's medium supplemented with a mixture of sodium hypoxanthine, aminopterin, and thymidine, 10% heat-inactivated fetal bovine serum, and 2 mM glutamine to 90% confluence. Cells were incubated with palonosetron (10 nM), granisetron (60 nM), and ondansetron (300 nM) for 2 h. Antagonist concentrations were approximately 50-fold Kd in each case to make sure receptors were saturated, based on Kd values described previously in NG108-15 or NIE-115 cells (Wong et al., 1995; Rojas et al., 2008). Subsequently, antagonists were removed and ondansetron or granisetron, two other widely used 5-HT3 receptor antagonists. The results suggest palonosetron differentially inhibits 5-HT3/NK-1 receptor signaling cross-talk and provide a rationale to explain palonosetron's unique efficacy against delayed emesis in the clinic.

**Animal Preparation.** Studies were conducted in accordance with the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Experiments were performed on adult male Sprague-Dawley rats weighing 270 to 350 g. Animals were housed in an animal facility with limited access. Room temperature was 22 ± 2°C, and relative humidity was set at 55 ± 10%. Artificial lighting was provided for 24 h with a cycle of 12-h light/12-h dark (light 7 AM–7 PM). Animals had free access to food and water; they were anesthetized with an intraperitoneal injection of a mixture of α-chloralose (80 mg/kg) and urethane (800 mg/kg). The anesthetic was supplemented every 3.5 h with an intravenous dose of 1/3 of the initial dose. Adequate depth of anesthesia was established in prior experiments by monitoring heart rate and withdrawal reflexes after subcutaneous electrical stimulation or pinching of the skin. Animals were ventilated with a respirator; a tracheal tube permitted artificial ventilation with room air (75–85 strokes/min, 3.5–4.0 cm3 tidal volumes). A midline abdominal incision exposed the abdominal vae-
gus, the stomach, and the duodenum. Stimulation of the subdia-
phragmatic vagus nerve was accomplished by placing a pair of Teflon-coated, pure-gold wire electrodes (outside diameter, 76 μm) around the anterior and posterior trunks, approximately 2 to 3 cm above the gastroesophageal junction, and above the accessory and celiac branches of the vagus nerves. These electrodes were loosely sutured to the esophagus to limit displacement.

**Drug Dosing.** Cisplatin (5 mg/kg) was given intraperitoneally, SP (10 μg/kg) was given by intra-arterial injection, and antagonists were administered by intravenous infusion. Antagonists were dis-
solved in 0.9% saline solutions and infused at a rate of 0.085 ml/min. Total dose of 38 mg/kg for ondansetron was administered over 30 min in 360 μg/100-μl solution. Total dose of 840 μg/kg for granisetron was administered over 10 min in 24 μg/100-μl solution. Total doses of 30, 100, and 300 μg/kg for palonosetron were administered over 10 min in 0.9, 3, and 9 μg/100-μl solutions, respectively.

**Recording of Single Nodose Neuronal Activity.** Rats were placed in a small animal stereotactic frame (David Kopf Instruments, Tujunga, CA). Body temperature was maintained with a heating pad. The right nodose ganglion was exposed by a short dorsal ap-
proach. Using an operating microscope, the ganglion sheath was removed and separated from the adjacent cervical sympathetic trunk and carotid artery. The recording microelectrodes were pulled from glass capillaries (A-M Systems, Everett, WA) using a micropipette puller and microelectrode beveler to obtain tips ranging between 0.08 to 0.1 μm in diameter with a resistance of 50 to 70 MΩ. The beveled glass microelectrode filled with 1.0 M KCl was lowered into the nodose ganglion. Once a nodose ganglion neuron activated by the elec-
trical vaginal stimulation was identified the response of that neuron to intra-arterial injection of SP was measured. Only gastrointestinal C-
fibers were recorded. The basal discharge was monitored for 2 min to confirm the stability of the basal firing frequency. Results shown in Figs. 2 to 5 are the average from 12 to 42 measurements made on isolated neurons obtained from 7 to 26 rats.

**Statistical Analysis.** Prism (GraphPad Software Inc., San Diego, CA) was used to obtain EC50 values in vitro experiments (sigmoidal dose-response variable slope). Errors correspond to S.E.M. of at least eight independent determinations. Student’s t test (two-tailed distribution) was used to determine p values. Experimental groups in the in vivo experiments included at least 12 independent neuronal measurements from at least seven rats to obtain average values. Error bars correspond to S.E.M.
S.E.M. Data are the average of at least eight independent determinations. EC_{50} values correspond to the results shown in Fig. 1. GraphPad Prism was used to obtain EC_{50} values (sigmoidal dose-response variable slope). Errors correspond to ± S.E.M. Data are the average of at least eight independent determinations. EC_{50} for SP was measured. Third, the neuronal response to palonosetron (Palon; 1 nM) was preincubated with cells for 2 h; antagonist was subsequently removed, and the effect on serotonin activation of the SP response was measured. Responses to SP and SP + 5HT in A are shown for reference. C and D, same as B except granisetron (Gran; 5 nM; C) and palonosetron (Palo; 1 nM; D) were used. Error bars correspond to ± S.E.M.; error bars in B–D for the SP and SP + 5HT traces are the same as in A. Each EC_{50} curve corresponds to the average of at least eight independent determinations.

### Table 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>EC_{50} ± S.E.M.</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP</td>
<td>6.7 ± 0.97</td>
</tr>
<tr>
<td>SP + 5-HT</td>
<td>0.62 ± 0.09</td>
</tr>
<tr>
<td>SP + 5-HT + ondansetron</td>
<td>0.66 ± 0.17</td>
</tr>
<tr>
<td>SP + 5-HT + granisetron</td>
<td>0.57 ± 0.10</td>
</tr>
<tr>
<td>SP + 5-HT + palonosetron</td>
<td>3.7 ± 0.84</td>
</tr>
</tbody>
</table>

10 µg/kg via intra-arterial injection neuronal activity was increased, although variable, to 4 ± 4 impulses/10 s. When measurement of the SP response was made 10 h after intraperitoneal administration of 5 mg/kg i.p. cisplatin (Fig. 2A), SP responses increased to 23 ± 3 impulses/10 s. When the dose of cisplatin was increased to 10 mg/kg, both basal and SP responses were similar within experimental error to when 5 mg/kg cisplatin was used (Fig. 2B). In short, there was an approximately 6-fold increase in the neuronal response to SP in the presence of 5 to 10 mg/kg cisplatin.

**Palonosetron Dose-Dependently Inhibited Cisplatin’s Potentiation of the SP Response in Nodose Ganglia.** Preliminary studies with the three antagonists suggested that only palonosetron had an effect on SP responses. Consequently, we conducted a dose response with palonosetron. Cisplatin (5 mg/kg i.p.) was administered to rats; 10 h later, single nodose ganglia neurons were isolated and four electrophysiological recordings were made at 10-min intervals (Fig. 3A). First, a basal reading was taken. Second, the neuronal response to SP (10 µg/kg intra-arterial injection) was measured. Third, the neuronal response to palonosetron (intravenous infusion of 30, 100, and 300 µg/kg) was measured. The fourth and final recording measured neuronal responses after the administration of SP (10 µg/kg intra-arterial injection). The first three responses were similar throughout the experiment: basal readings were 7.5 ± 3
impulses/10 s. SP increased the neuronal activity to 38 ± 4 impulses/10 s, and palonosetron alone at 30, 100, or 300 µg/kg did not have an effect on either basal or SP-induced responses. However, when SP was administered after palonosetron, the neuronal responses dose-dependently decreased to 32 ± 4 (SP + 30 µg/kg palonosetron), 18 ± 2 (SP + 100 µg/kg palonosetron), and 9 ± 3 (SP + 300 µg/kg palonosetron) impulses/10 s (Fig. 3B).

**Ondansetron and Granisetron Had No Effect on the Cisplatin Enhancement of the SP Response in Nodose Ganglia.** Because palonosetron exhibited inhibition of the cisplatin-induced SP response, we explored more thoroughly whether the effect was common to other 5-HT₃ receptor antagonists such as granisetron and ondansetron. In an attempt to replicate the results with ondansetron and granisetron, experimental doses that accounted for their differences in clinical dose versus palonosetron were chosen. Specifically, we calculated the experimental dose by taking the difference in clinical dose between palonosetron and ondansetron (approximately 128-fold) and multiplying it by the most effective palonosetron dose tested in our model (300 µg/kg × 128 = 38 mg/kg). Likewise, the dose for granisetron was calculated by the difference in clinical dose between palonosetron and granisetron (approximately 2.8-fold) multiplied by the most effective palonosetron dose (300 µg/kg × 2.8 = 840 µg/kg).

The doses used for ondansetron and granisetron in these studies turned out to be in excess of their active doses reported in previous efficacy studies in animals (Eglen et al., 1995; Rudd and Naylor, 1996; Endo et al., 1999; Rudd et al., 2002). Vagal nerve activity was measured in animals 10 h after cisplatin administration (5 mg/kg i.p.). The same measurements as in the palonosetron dose-dependence experiment were made: basal response to SP, response to each antagonist alone, and response to administration of SP (Fig. 4A). Basal and SP responses were 8 ± 3 and 33 ± 6 impulses/10 s, respectively. Neither ondansetron (38 mg/kg i.v.) nor granisetron (840 µg/kg i.v.) had an effect on the basal response. When SP was administered after ondansetron or granisetron, the SP response was not affected. This lack of effect was in stark contrast to more than 70% inhibition of the SP response after palonosetron administration (Fig. 4B).

**Palonosetron’s Inhibition of the Cisplatin-Induced SP Response Was Time-Dependent.** One major consideration in these experiments and in the clinic is the time of administration of 5-HT₃ receptor antagonist with respect to the time of administration of the chemotherapeutic agent. In the experiments described thus far, the antagonists were administered 10 h after cisplatin. We wanted to explore whether inhibition of the SP response could be observed at earlier time points. To this end, we explored the inhibition of the neuronal response to SP when antagonists were administered 30 min before and 5 and 10 h after cisplatin. As above, the measurement of the neuronal response to SP was made 10 h after cisplatin (Fig. 5A). The neuronal response to SP administration in the presence of cisplatin was 32 ± 4 impulses/10 s. When ondansetron (38 mg/kg i.v.) or granisetron (840 µg/kg i.v.) was given at either 30 min before or 5 and 10 h after cisplatin, there was no effect on the SP response. In contrast, when palonosetron (300 µg/kg i.v.) was administered at 30 min before or 5 and 10 h after cisplatin, inhibition of the SP response was observed at every time point. There was 33 ± 7% inhibition when palonosetron was administered 30 min before cisplatin, 70 ± 8% inhibition when palonosetron was given 5 h after cisplatin, and 78 ± 10% inhibition when palonosetron was given 10 h after cisplatin (Fig. 5B).

**Discussion**

5-HT₃ and NK-1 receptor antagonists are common therapy to help prevent CINV. In general, 5-HT₃ receptor antagonists are efficacious in the acute (0–24 h) phase of CINV, whereas NK-1 receptor antagonists are most efficacious during the delayed (24–120 h) phase (Hesketh et al., 2003). Palonosetron is the only 5-HT₃ receptor antagonist that is labeled for the treatment of delayed emesis in moderately emetogenic chemotherapy. The mechanisms by which palonosetron helps prevent delayed emesis are not known; this is tantalizing given that palonosetron does not bind to the NK-1 receptor (Wong et al., 1995). On the other hand, palonosetron has been shown to exhibit unique molecular interactions with the 5-HT₃ receptor. Palonosetron exhibits allosteric binding and positive cooperativity (Rojas et al., 2008) and triggers receptor internalization and long-term inhibition of receptor function (Rojas et al., 2010), attributes not shared by other 5-HT₃ receptor antagonists.

Various reports in the literature have shown that there is cross-talk between NK-1 and 5-HT₃ receptor signaling path-
ways (Hu et al., 2004). SP, a known agonist at the NK-1 receptor, was shown to potentiate 5-HT₃ receptor-mediated inward current in rat trigeminal ganglion neurons. Potentiation of 5-HT₃ receptor current through SP is thought to involve second-messenger signaling that culminates in protein kinase C activation (Hu et al., 2004). In addition, 5-HT₂ receptors have been shown to block SP-mediated vagal afferent activation, and NK-1 antagonists were shown to block serotonin-induced vagal afferent activation (Minami et al., 2001). Evidence of receptor signaling interaction raises the interesting possibility that palonosetron’s unique efficacy to inhibit serotonin-induced calcium-ion influx (Supplemental Methods and Supplemental Fig. 1, A–C; IC₅₀ values were 0.7, 2, and 3 nM for palonosetron, granisetron, and ondansetron, respectively). These concentrations were also approximately 50 times their previously determined Kᵰ values (Wong et al., 1995; Rojas et al., 2010). When cells were preincubated with excess palonosetron (10 nM) followed by the drug’s removal
tron's distinctive ability to induce 5-HT3 receptor internalization from the media. Previously, we have shown palonosetron rapidly partitions inside cells along with the 5-HT3 receptor during antagonist preincubation; once inside the cell, palonosetron does not reappear in the extracellular milieu for at least 2 h. It is noteworthy that palonosetron's internalization depends on the presence of the 5-HT3 receptor, because palonosetron was shown not to partition into cells that do not express the 5-HT3 receptor (Rojas et al., 2010). These data suggest that palonosetron's unique effect on inhibition of serotonin-induced SP activation is a 5-HT3 receptor-mediated difference, not a cell permeability difference.

To determine whether the in vitro results could also be demonstrated in vivo, we examined neuronal responses in nodose ganglia to SP after cisplatin administration in rats. We used rat nodose ganglia because they have been shown to express both 5-HT3 and NK-1 receptors (Hu et al., 2004) and cisplatin because it is known to activate the mechanisms of both acute and delayed emesis (Hesketh, 2008). Cisplatin triggers the release of serotonin from enterochromafin cells, which in turn activates 5-HT3 receptors located on the surface of vagal afferents. Consistent with previous data showing that 5-HT3 receptor activity can influence NK1 signaling (Minami et al., 2001; Hu et al., 2004), we found that pretreatment of rats with cisplatin induced a 3- to 6-fold increase of the neuronal response in nodose ganglia to SP (Fig. 2) in agreement with a previous report (Wu et al., 2009).

Because cisplatin potentiated the SP response in nodose ganglia, we explored the possibility that 5-HT3 receptor antagonists could inhibit the cisplatin-induced activation of the SP response. We found that palonosetron uniquely inhibited the cisplatin-induced neuronal response to SP in a dose-dependent manner 10 h after cisplatin administration (Figs. 3 and 4). Neither ondansetron nor granisetron had an effect. It is noteworthy that the doses of ondansetron and granisetron in these studies took into account differences in clinical dose and were higher than those used in animal models where efficacy with these antagonists was observed (Eglen et al., 1995; Rudd and Naylor, 1996; Endo et al., 1999; Rudd et al., 2002). Consequently, the lack of inhibition of SP response with the high doses of granisetron and ondansetron used obviated the need for evaluating the efficacy of lower doses. One limitation, however, is that even though these antagonists are thought to be selective for the 5-HT3 receptor the compounds could be acting on off-target sites that could affect neuronal activity in the nodose ganglia at the relatively high doses used. Minami et al. (2001) reported that granisetron inhibits the SP response under acute conditions in vivo. However, our in vivo study was different in that it was designed to explore the effect of 5-HT3 receptor antagonists on the delayed cisplatin-induced plasticity changes characterized by an enhanced SP response (Wu et al., 2009). Correspondingly, the experiment outlined in Fig. 4 involved measurements of the SP response 10 h after cisplatin administration and the potential effects of 5-HT3 receptor antagonists on this enhancement. Under these conditions only palonosetron inhibited the enhanced interaction of SP and serotonin in vagal afferent neurons. These differences probably are caused by palonosetron-triggered 5HT3 receptor internalization that is unique and would be predicted to provide more persistent 5HT3 receptor functional inhibition compared with simple...
binding followed by dissociation at the receptor on the cell surface as occurs with ondansetron and granisetron. Because the time of antiemetic administration could have different effects on cisplatin-induced toxicity in the clinic, we also explored the time dependence of palonosetron inhibition of the cisplatin-induced neuronal response to SP and the potential that ondansetron and/or granisetron could also have an effect if administered at times other than 10 h after cisplatin administration. Additional studies were performed when antagonists were given 30 min before cisplatin and 5 h after cisplatin. When ondansetron or granisetron was used, no inhibition of the cisplatin effect was observed at either time point. In contrast, when palonosetron was administered 30 min before cisplatin or 5 h after cisplatin and the effect on SP activity was measured 10 h later 33 ± 7 and 70 ± 8% inhibition was observed, respectively (Fig. 5). In short, palonosetron inhibition of the SP response could be seen when palonosetron was administered 10 h, 5 h, or 10 min before measurement of the SP response.

The half-life of palonosetron in the rat is 90 min after intravenous administration (Supplemental Data, Palonosetron Rat PK Report), which is in the same order of magnitude as the half-lives previously reported for ondansetron (20–40 min) (Yang and Lee, 2008) and granisetron (50 min) (Huang et al., 1999) in rats. Therefore, the differences we observed probably are not caused by differences in pharmacokinetics.

In summary, palonosetron uniquely inhibits cross-talk between the 5-HT3 and NK-1 receptor pathways in a dose- and time-dependent fashion. Our results are consistent with previous data showing that palonosetron exhibits distinct pharmacology versus the older 5-HT3 receptor antagonists and provide a rationale for the unique efficacy observed with palonosetron in delayed CINV in the clinic.

References
kinin NK1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK1(1) and 5-HT(3) receptors. Eur J Pharmacol 428: 215–220.
Rojas C, Stathis M, Thomas AG, Massuda EB, Massuda EB, Alt J, Zhang J, Ruben-
col 626:193–199.
isetron plus dexamethasone for the prevention of nausea and vomiting during chemother-

Address correspondence to: Dr. Barbara S. Slusher, The Brain Science Institute, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Suite 370, Baltimore, MD 21205. E-mail: bslusher@jhmi.edu
The antiemetic 5-HT₃ receptor antagonist palonosetron inhibits Substance P-mediated responses *in vitro and in vivo*

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra and Barbara S. Slusher

The Journal of Pharmacology and Experimental Pharmaceutics

Supplemental Figure 1 A: Inhibition of serotonin-induced calcium influx in cells by palonosetron. Results correspond to an average of at least 3 independent determinations.
The antiemetic 5-HT₃ receptor antagonist palonosetron inhibits Substance P-mediated responses in vitro and in vivo.

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra and Barbara S. Slusher

The Journal of Pharmacology and Experimental Pharmaceutics

Supplemental Figure 1 B: Inhibition of serotonin-induced calcium influx in cells by granisetron. Results correspond to an average of at least 3 independent determinations.
The antiemetic 5-HT₃ receptor antagonist palonosetron inhibits Substance P-mediated responses in vitro and in vivo

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra and Barbara S. Slusher

The Journal of Pharmacology and Experimental Pharmaceutics

Supplemental Figure 1 C: Inhibition of serotonin-induced calcium influx in cells by ondansetron. Results correspond to an average of at least 3 independent determinations.
The antiemetic 5-HT$_3$ receptor antagonist palonosetron inhibits Substance P-mediated responses in vitro and in vivo

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra and Barbara S. Slusher

The Journal of Pharmacology and Experimental Pharmaceutics

Effect of 5-HT$_3$ receptor antagonists on serotonin-induced calcium-ion influx

**Methods** – Cells were placed on glass-bottomed dishes treated with poly-D-lysine and allowed to grow for at least four days to confluency in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine. Cells were rinsed with F-12/Dulbecco’s modified Eagle’s medium, incubated in Fluo-4 (2 µM Molecular Probes) for 1 h at room temperature, washed and assayed using the FLIPR. Cells were then treated with various concentrations of ondansetron, granisetron or palonosetron and after 2 min preincubation cells were challenged with 10 µM serotonin. Preliminary control experiments had shown that the EC$_{50}$ for serotonin-induced calcium-ion influx was 500 nM and maximal response was obtained in the range 1 – 30 µM.
The antiemetic 5-HT3 receptor antagonist palonosetron inhibits Substance P-mediated responses in vitro and in vivo

Camilo Rojas, Ying Li, Jie Zhang, Marigo Stathis, Jesse Alt, Ajit G. Thomas, Sergio Cantoreggi, Silvia Sebastiani, Claudio Pietra and Barbara S. Slusher

The Journal of Pharmacology and Experimental Pharmaceutics

PALONOSETRON RAT PK
Drugs: RS-25259-197 (palonosetron)
Report Number: DM 995

METABOLIC DISPOSITION FOLLOWING SINGLE INTRAVENOUS AND ORAL DOSES OF [14C]-RS-25259-197 AND TISSUE DISTRIBUTION AFTER A SINGLE INTRAVENOUS DOSE OF [14C]-RS-25259-197 TO RATS

Levels of total radioactivity in whole blood, plasma, urine, and feces were determined following administration of single 0.5 mg/kg intravenous and oral doses of [14C]-RS-25259-197 (hydrochloride salt) to male Sprague Dawley rats.

After the intravenous dose, mean recoveries of total radioactivity (0-96 hr) were 56.2% of the administered dose in urine and 33.9% of the dose in feces. After the oral dose, mean recoveries of total radioactivity (0-96 hr) were 50.8% of the administered dose in urine and 40.7% of the dose in feces.

Levels of total radioactivity in selected tissues were determined following the single intravenous dose of [14C]-RS-25259-197. The rank order of total radioactivity in tissues (based on 0-96 hr AUC) was: bladder, ileum, large intestine, caecum, small intestine(-ileum), kidneys, lungs, liver, adrenals, testes, stomach, spleen, skin, bone marrow, heart, skeletal muscle, eyes, total femur, plasma, cerebrum/cerebellum, abdominal fat, femur (without marrow) and medulla. Distribution of radioactivity into tissues was extensive. Depletion of total radioactivity from tissue generally paralleled elimination of total radioactivity 1-4 hr after dosing. Maximal tissue/plasma concentration ratios of radioactivity in medulla and cerebrum/cerebellum occurred 30 min after dosing and were 1.65 and 1.17, respectively. Chromatographic analysis of radioactivity extracted from brain detected only RS-25259.

By either route of administration, chromatographic analysis of plasma extracts showed eight metabolites of RS-25259-197. Pharmacokinetic parameters based on concentrations in plasma pooled from rats (N=3 per time point) for total radioactivity, RS-25259-197 and two principal metabolites following the intravenous administration of [14C]-RS-25259-197 were as follows:
<table>
<thead>
<tr>
<th>Intravenous Parameter</th>
<th>Total Radioactivity</th>
<th>RS-25259-197</th>
<th>Metabolite 1</th>
<th>Metabolite 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC 0-24 hr (ng-Eq•hr/mL)</td>
<td>171</td>
<td>58.9</td>
<td>46.3</td>
<td>19.7</td>
</tr>
<tr>
<td>% AUC</td>
<td>100</td>
<td>34.5</td>
<td>27.1</td>
<td>11.6</td>
</tr>
<tr>
<td>T 1/2 (hr)</td>
<td>1.79</td>
<td>1.49</td>
<td>1.50</td>
<td>2.13</td>
</tr>
<tr>
<td>C max (ng-Eq/mL)</td>
<td>75.7</td>
<td>58.3</td>
<td>11.9</td>
<td>5.68</td>
</tr>
<tr>
<td>T max (hr)</td>
<td>0.083</td>
<td>0.083</td>
<td>0.25</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Individually, the remaining metabolites in plasma following the intravenous dose were less than 4% of the AUC for total radioactivity. For RS-25259-197, systemic clearance (CL) was 7.96 L•kg⁻¹•hr⁻¹ and volume of distribution (β) was 17.1 L•kg⁻¹.

Pharmacokinetic parameters based on concentrations in plasma pooled from rats (N=3 per time point) for total radioactivity, RS-25259-197 and two principal metabolites following the oral administration of [¹⁴C]-RS-25259-197 were as follows:

<table>
<thead>
<tr>
<th>Oral Parameter</th>
<th>Total Radioactivity</th>
<th>RS-25259-197</th>
<th>Metabolite 1</th>
<th>Metabolite 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC 0-24 hr (ng-Eq•hr/mL)</td>
<td>171</td>
<td>3.94</td>
<td>71.5</td>
<td>30.6</td>
</tr>
<tr>
<td>% AUC</td>
<td>100</td>
<td>2.30</td>
<td>41.8</td>
<td>17.9</td>
</tr>
<tr>
<td>T 1/2 (hr)</td>
<td>2.07</td>
<td>ND</td>
<td>1.23</td>
<td>2.21</td>
</tr>
<tr>
<td>C max (ng-Eq/mL)</td>
<td>119</td>
<td>0.964</td>
<td>70.3</td>
<td>21.7</td>
</tr>
<tr>
<td>T max (hr)</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
</tr>
</tbody>
</table>

ND is not determined

Individually, the remaining metabolites in plasma following the oral dose were less than 6% of the AUC for total radioactivity. The oral bioavailability of RS-25259-197 was 6.41%.

Chromatographic analysis of extracts of pooled rat urine revealed seven metabolites which collectively accounted for 89% and 92% of all radioactivity recovered in urine for the intravenous and oral doses, respectively. Little RS-25259-197 was recovered in urine after the intravenous dose (4.4% of the dose) and no RS-25259-197 was recovered after the oral dose. The major urinary metabolite was Metabolite 1 (6-hydroxy-RS-25259) which represented 33.4% and 30.1% of the intravenous and oral doses, respectively. Individually, the remaining metabolites represented less than 4% of the intravenous dose and less than 9% of the oral dose.